Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial
- Hosseinipour, Mina C
- Bisson, Gregory P
- Miyahara, Sachiko
- Sun, Xin
- Moses, Agnes
- Riviere, Cynthia
- Kirui, Fredrick K
- Badal-Faesen, Sharlaa
- Lagat, David
- Nyirenda, Mulinda
- Naidoo, Kogieleum
- Hakim, James
- Mugyenyi, Peter
- Henostroza, German
- Leger, Paul D
- Lama, Javier R
- Mohapi, Lerato
- Alave, Jorge
- Mave, Vidya
- Veloso, Valdilea G
- Pillay, Sandy
- Kumarasamy, Nagalingeswaran
- Bao, Jing
- Hogg, Evelyn
- Jones, Lynne
- Zolopa, Andrew
- Kumwenda, Johnstone
- Gupta, Amita
Publication date
January 2016
DOIAbstract
Mortality within the first 6 months after initiating antiretroviral therapy (ART) is common in resource-limited settings and is often due to tuberculosis (TB) among patients with advanced HIV disease. Isoniazid preventive therapy (IPT) is recommended in HIV-infected adults, but sub-clinical TB can be difficult to diagnose. We hypothesized that empiric TB treatment would reduce early mortality compared to IPT in high-burden settings
Add to ORKG